Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones
Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good progress; target validation and details of mechanism of action expected in Q1 2025
Cell therapy INV441: pre-IND meeting with US FDA successfully completed; first-in-humans study in glioblastoma to start mid-2025 as part of a new collaboration with DFCI
invIOs management to participate in LSX Inv€$tival Showcase™ in London on November 18th
VIENNA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH ("invIOs"), a privately held biotechnology company developing novel therapies for cancer, today announced that the company has raised €8.2 million in a Series A fundraising that includes strong participation from existing shareholders and Ligand Pharmaceuticals. Ligand recently acquired APEIRON, the former parent company of invIOs. This funding secures ongoing pipeline progress and achievement of clinical and preclinical milestones through 2025.
Peter Llewellyn-Davies, CEO & CFO of invIOs, said: "We are pleased to have raised these funds, which enables us to move our programs forward as planned. I am particularly grateful for the strong support of existing shareholders, as well as the commitment of our new shareholder, Ligand Pharmaceuticals."
invIOs also provided an update on recent progress with its two lead anti-cancer programs, INV441 and INV501. The company has collaborations in glioblastoma with the Dana-Farber Cancer Institute (DFCI) for both programs. The collaborations are being led by David Reardon, MD, Clinical Director, Center for Neuro-Oncology at the DFCI and Professor of Medicine at Harvard Medical School. Dr. Reardon is a world-renowned expert in brain cancer, particularly glioblastoma research ...
